

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 May 2010

Section H for April and May 2010



Contents

Summary of PHARMAC decisions effective 1 May 2010	3
Gemcitabine hydrochloride and vinorelbine – access widening.....	5
Lignocaine urethral syringe – new listing	5
Blood Glucose Test Strip – claiming reminder.....	5
Sumatriptan – Arrow-Sumatriptan tablets smaller pack size continued availability.....	6
Diclofenac sodium – delisting of alternative brands.....	6
Moclobemide – delisting of GenRx Moclobemide brand	6
Tri-phasic oral contraceptives – delisting	7
Testosterone undecanoate capsules	7
Minerals – amendment to presentation descriptions	7
Laxofest – presentation amendment	7
Tender News.....	8
Looking Forward	8
Sole Subsidised Supply products cumulative to May 2010.....	9
New Listings.....	18
Changes to Restrictions.....	19
Changes to Subsidy and Manufacturer’s Price.....	22
Changes to Sole Subsidised Supply	23
Delisted Items	24
Items to be Delisted	25
Section H changes to Part II	27
Section H changes to Part IV	29
Index	30

Summary of PHARMAC decisions

EFFECTIVE 1 MAY 2010

New listings (page 18)

- Bendrofluazide (Arrow-Bendrofluazide) tab 2.5 mg – up to 150 tab available on a PSO
- Bendrofluazide (Arrow-Bendrofluazide) tab 5 mg
- Testosterone undecanoate (Arrow-Testosterone) cap 40 mg – Retail pharmacy-Specialist
- Lignocaine (Pfizer) gel 2%, 10 ml urethral syringe
- Fluorouracil sodium (Fluorouracil Ebewe) inj 50 mg per ml, 10 ml, 5 inj pack – PCT only – Specialist

Changes to restrictions (pages 19-21)

- Docusate sodium cap 50 mg (Laxofast 50) and cap 120 mg (Laxofast 120) – amended presentation
- Calcium carbonate (Calsource) tab eff 1.75 g (1 g elemental) – chemical and presentation description amended, and addition of elemental strength
- Calcium carbonate tab 1.25 g (500 mg elemental) (Calci-Tab 500) and tab 1.5 g (600 mg elemental) (Calci-Tab 600) – addition of elemental strength
- Sodium fluoride (PSM) tab 1.1 mg (0.5 mg elemental) – addition of elemental strength
- Ferrous fumarate (Ferro-tab) tab 200 mg (65 mg elemental) – addition of elemental strength
- Ferrous fumarate with folic acid (Ferro-F-Tabs) tab 310 mg (100 mg elemental) with folic acid 350 μ g – addition of elemental strength
- Ferrous gluconate with ascorbic acid (Healtheries Iron with Vitamin C) tab 170 mg (20 mg elemental) with ascorbic acid 40 mg – addition of elemental strength
- Ferrous sulphate (Ferro-Gradumet) tab long-acting 325 mg (105 mg elemental) and (Ferodan) oral liq 150 mg per 5 ml (30 mg elemental per 1 ml) – addition of elemental strength
- Ferrous sulphate with folic acid (Ferrograd-Folic) tab long-acting 325 mg (105 mg elemental) with folic acid 350 μ g – addition of elemental strength
- Magnesium sulphate (Mayne) inj 49.3%, 5 ml – amended presentation
- Zinc sulphate (Zincaps) cap 137.4 mg (50 mg elemental) – addition of elemental strength
- Gemcitabine hydrochloride (Gemcitabine Ebewe and Gemzar) inj 200 mg and 1 g, and (Baxter) inj 1 mg for ECP – amended Special Authority criteria
- Vinorelbine (Navelbine and Vinorelbine Ebewe) inj 10 mg per ml, 1 ml and 5 ml, and (Baxter) inj 1 mg for ECP – amended Special Authority criteria

Summary of PHARMAC decisions – effective 1 May 2010 (continued)

Decreased subsidy (page 22)

- Crotamiton (Eurax) crm 10%
- Chlorhexidine gluconate (Orion) handrub 1% with ethanol 70%
- Pregnancy tests – hCG urine (MDS Quick Card) cassette, 25 test OP
- Lamivudine (3TC) tab 150 mg and oral liq 10 mg per ml
- Cisplatin (Cisplatin Ebewe) inj 1 mg per ml, 50 ml and 100 ml
- Megestrol acetate (Megace) tab 160 mg

Sumatriptan – Arrow-Sumatriptan smaller pack size continued availability

Arrow-Sumatriptan tab 50 mg (4 tablet pack) and 100 mg (2 tablet pack) will remain fully subsidised and will not be delisted from 1 May 2010 as previously notified.

The smaller pack sizes will continue to be listed in the Pharmaceutical Schedule at their current prices and subsidies until stock is

exhausted, when PHARMAC will provide six months notice before delisting them from the Pharmaceutical Schedule.



Diclofenac sodium – delisting of alternative brands

The Apo-Diclo SR brand of diclofenac sodium long-acting 75 mg and long-acting 100 mg tablets will be delisted from the Pharmaceutical Schedule from 1 November 2010 as supplies of this brand are now exhausted.

The Diclax SR brand of both strengths in the 500-tablet pack size will remain fully

subsidised; however, the 30-tablet pack size of Diclax SR 75 mg tablets will be delisted from 1 August 2010.

As notified in the April 2010 Update to the Pharmaceutical Schedule, the Voltaren SR brand of diclofenac sodium 75 mg long-acting tablets will be delisted from 1 June 2010.

Moclobemide – delisting of GenRx Moclobemide brand

Supply of the Apo-Moclobemide brand of moclobemide tablets 150 mg and 300 mg has recently been resumed. As a result, the GenRx Moclobemide brand will be delisted from the Pharmaceutical Schedule from 1 November 2010. Sole Supply Status for Apo-Moclobemide will be reinstated from 1 November 2010.



Tri-phasic oral contraceptives – delisting

PHARMAC has received notice that the last remaining supplier of subsidised tri-phasic oral contraceptives intends to discontinue from the New Zealand market. Trifeme will be delisted from 1 November 2010 (six months after notification from the supplier of stock depletion).

The Hormone and Contraceptive Subcommittee of PTAC considered that there was no clinical need for a tri-phasic oral contraceptive to be subsidised and that Brevinor 1 would be an appropriate alternative.

Testosterone undecanoate capsules

On 24 December 2009 PHARMAC notified that Arrow Pharmaceuticals brand of testosterone undecanoate – Arrow-Testosterone - had been awarded the 2008/09 Tender. The listing for this product was delayed by 3 months, until 1 May 2010. This will result in all the timelines for the tender process being moved by the

same period of time. The listing of Arrow-Testosterone will occur on 1 May 2010, reference pricing of non-tender winning brands, Andriol Testocaps and Panteston, will occur on 1 July 2010 and Sole Subsidised Supply for Arrow-Testosterone will commence on 1 October 2010.

Minerals – amendment to presentation descriptions

Following suggestions from healthcare professionals and a review by PHARMAC staff the line item descriptions of mineral products in the Pharmaceutical Schedule have been amended. The line item descriptions now specify the content of

elemental content in brackets as well as the total weight of the salt form. This is expected to aid prescribers and pharmacists when determining dosage of minerals to prescribe/dispense. Full details of the changes can be found on page 19.

Laxofast – presentation amendment

The presentation of the Laxofast brand of docusate sodium (Laxofast 50 and Laxofast 120) has been amended from tablets to capsules. The presentation was listed as

tablets last month when they are in fact capsules. PHARMAC would like to apologise for any confusion this may have caused.

Tender News

Sole Subsidised Supply changes – effective 1 June 2010

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Flucloxacillin sodium	Cap 250 mg; 250 cap	AFT (AFT)
Flucloxacillin sodium	Cap 500 mg; 500 cap	AFT (AFT)
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg; 100 tab	ParaCode (Arrow)
Pindolol	Tab 5 mg; 100 tab	Apo-Pindolol (Apotex)
Pindolol	Tab 10 mg; 100 tab	Apo-Pindolol (Apotex)
Pindolol	Tab 15 mg; 100 tab	Apo-Pindolol (Apotex)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Decision for implementation 1 June 2010

- Risperidone (Ridal) tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg – subsidy decrease

Decision for implementation 1 July 2010

- Metoprolol succinate (AFT-Metoprolol CR and Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – subsidy decrease

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Acarbose	Tab 50 mg & 100 mg	Glucobay	2012
Acetazolamide	Tab 250 mg	Diamox	2011
Allopurinol	Tab 100 mg & 300 mg	Apo-Allopurinol	2011
Alprazolam	Tab 250 µg, 500 µg & 1 mg	Arrow-Alprazolam	2010
Amantadine hydrochloride	Cap 100 mg	Symmetrel	2011
Amlodipine	Tab 5 mg & 10 mg	Apo-Amlodipine	2011
Amoxicillin	Grans for oral liq 250 mg per 5 ml	Ospamox Ospamox Paediatric Drops	2012
	Drops 125 mg per 1.25 ml		2011
	Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg	Ibiamox Apo-Amoxi	2010
Amoxicillin clavulanate	Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	Curam	2012
	Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	Curam	
	Tab amoxicillin 500 mg with potassium clavulanate 125 mg	Synermox	2011
Aqueous cream	Crn 500 g	AFT	2011
Aspirin	Tab dispersible 300 mg	Ethics Aspirin	2010
	Tab 100 mg	Ethics Aspirin EC	
Atenolol	Tab 50 mg & 100 mg	Pacific Atenolol	2012
Atropine sulphate	Inj 600 µg, 1 ml	AstraZeneca	2012
Azithromycin	Tab 500 mg	Arrow-Azithromycin	2012
Baclofen	Tab 10 mg	Pacifen	2012
Benzylpenicillin sodium (Penicillin G)	Inj 1 mega u	Sandoz	2011
Betamethasone valerate	Scalp app 0.1%	Beta Scalp	2012
Bezafibrate	Tab 200 mg	Fibalip	2011
Bicalutamide	Tab 50 mg	Bicalox	2011
Bisacodyl	Tab 5 mg	Lax-Tabs	2010
Brimonidine tartrate	Eye drops 0.2%	AFT	2011
Bupivacaine hydrochloride	Inj 0.5%, 4 ml	Marcaïn Isobaric	2010
	Inj 0.5%, 8% glucose, 4 ml	Marcaïn Heavy	
Calamine	Crn, aqueous, BP Lotn, BP	healthE API	2012
Calcitonin	Inj 100 iu per ml, 1 ml	Miacalcic	2011
Calcitriol	Cap 0.25 µg & 0.5 µg	Airflow	2012
Calcium	Tab eff 1 g	Calsource	2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Calcium folinate	Inj 50 mg	Calcium Folate Ebewe	2011
Captopril	Tab 12.5 mg, 25 mg & 50 mg	Apo-Captopril	2010
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy-Cefaclor Ranbaxy-Cefaclor	2010
Cefazolin sodium	Inj 500 mg & 1 g	Hospira	2011
Cefuroxime sodium	Inj 750 mg & 1.5 g	Zinacef	2011
Cephalexin monohydrate	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Cefalexin Sandoz Cefalexin Sandoz	2012
Cetomacrogol	Crn BP	PSM	2010
Cetirizine hydrochloride	Tab 10 mg Oral liq 1 mg per ml	Zetop Cetirizine-AFT	2011
Chloramphenicol	Eye oint 1%	Chlorsig	2012
Chlorhexidine gluconate	Soln 4%	Orion	2011
Ciclopiroxolamine	Nail soln 8%	Batrafen	2012
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Rex Medical	2011
Citalopram	Tab 20 mg	Arrow-Citalopram	2011
Clarithromycin	Tab 250 mg Grans for oral liq 125 mg per 5 ml	Klamycin Klacid	2010
Clobetasol propionate	Crn 0.05% Oint 0.05% Scalp app 0.05%	Dermol Dermol Dermol	2012
Clonazepam	Tab 500 µg & 2 mg	Paxam	2011
Clonidine	TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day	Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3	2012
Clonidine hydrochloride	Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg	Catapres Dixarit Catapres	2012
Clotrimazole	Crn 1% Vaginal crn 1% with applicator(s) Vaginal crn 2% with applicators(s)	Clomazol Clomazol Clomazol	2011 2010
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2010
Colchicine	Tab 500 µg	Colgout	2010
Colestipol hydrochloride	Sach 5 g	Colestid	2010
Colistin sulphomethate	Inj 150 mg	Colistin-Link	2010
Compound electrolytes	Powder for soln for oral use	Enerlyte	2010
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2012
Cyclophosphamide	Tab 50 mg	Cycloblastin	2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2012
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs	Ginet 84	2011
Desferrioxamine mesylate	Inj 500 mg	Mayne	2010
Desmopressin	Nasal spray 10 µg per dose	Desmopressin-PH&T	2011
Dexamphetamine sulphate	Tab 5 mg	PSM	2010
Dextrose	Inj 50%, 10 ml	Biomed	2011
Dextrose with electrolytes	Oral soln with electrolytes	Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit	2010
Diclofenac sodium	Tab EC 25 mg & 50 mg	Diclohexal	2012
	Eye drops 1 mg per ml	Voltaren Ophtha	2011
	Inj 25 mg per ml, 3 ml	Voltaren	
	Suppos 12.5 mg, 25 mg, 50 mg & 100 mg	Voltaren	
Diltiazem hydrochloride	Tab 30 mg & 60 mg	Dilzem	2011
	Cap long-acting 120 mg, 180 mg & 240 mg	Cardizem CD	
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2011
Doxazosin mesylate	Tab 2 mg & 4 mg	Apo-Doxazosin	2010
Emulsifying ointment	Oint BP	AFT	2011
Enoxaparin sodium (low molecular weight heparin)	Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg	Clexane	2012
Entacapone	Tab 200 mg	Comtan	2012
Erythromycin ethyl succinate	Tab 400 mg	E-Mycin	2012
	Grans for oral liq 200 mg per 5 ml	E-Mycin	2011
	Grans for oral liq 400 mg per 5 ml	E-Mycin	
Ethinylloestradiol	Tab 10 µg	NZ Medical and Scientific	2012
Ethinylloestradiol with norethisterone	Tab 35 µg with norethisterone 500 µg	Brevinor 21	2010
	Tab 35 µg with norethisterone 1 mg	Brevinor 1/21	
	Tab 35 µg with norethisterone 1 mg and 7 inert tab	Brevinor 1/28	
Etidronate disodium	Tab 200 mg	Arrow-Etidronate	2012
Felodipine	Tab long-acting 5 mg	Felo 5 ER	2012
	Tab long-acting 10 mg	Felo 10 ER	
Ferrous sulphate	Oral liq 150 mg per 5 ml	Ferodan	2010
Finasteride	Tab 5 mg	Fintral	2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Flucloxacillin sodium	Grans for oral liq 125 mg per 5 ml	AFT	2012
	Grans for oral liq 250 mg per 5 ml	AFT	
	Inj 250 mg, 500 mg & 1 g	Flucloxin	2011
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Pacific	2011
Fludarabine phosphate	Inj 50 mg	Fludara	2011
	Tab 10 mg	Fludara Oral	
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g	Ultraproct	2010
	Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg	Ultraproct	
Fluoromethalone	Eye drops 0.1%	FML	2012
Fluoxetine hydrochloride	Cap 20 mg	Fluox	2010
	Tab disp 20 mg, scored	Fluox	
Fluticasone propionate	Metered aqueous nasal spray, 50 µg per dose	Flixonase Hayfever & Allergy	31/1/13
Furosemide	Tab 40 mg	Diurin 40	2012
Fusidic acid	Crn 2%	Foban	2010
	Oint 2%	Foban	
Gabapentin	Cap 100 mg, 300 mg & 400 mg	Nupentin	31/7/12
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2012
Gliclazide	Tab 80 mg	Apo-Gliclazide	2011
Glipizide	Tab 5 mg	Minidiab	2011
Glyceryl trinitrate	Tab 600 µg	Lycinate	2011
	Oral pump spray 400 µg per dose	Nitrolingual Pumpspray	
	TDDS 5 mg & 10 mg	Nitroderm TTS	
Haloperidol	Oral liq 2 mg per ml	Serenace	2010
	Tab 500 µg, 1.5 mg & 5 mg	Serenace	
Hydrocortisone	Tab 5 mg & 20 mg	Douglas	2012
	Powder	ABM	2011
	Crn 1%	PSM	
Hydrocortisone acetate	Rectal foam 10%, CFC-free (14 applications)	Colifoam	2012
Hydrocortisone butyrate	Scalp lotn 0.1%	Locoid	2010
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrous 3% and mineral oil	DP Lotn HC	2011
Hydroxychloroquine sulphate	Tab 200 mg	Plaquenil	2012
Hypromellose	Eye drops 0.5%	Methopt	2011
Hysocine N-butylbromide	Inj 20 mg, 1 ml	Buscopan	2011
	Tab 20 mg	Gastrosoothe	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Ibuprofen	Tab 200 mg Oral liq 100 mg per 5 ml	Ethics Ibuprofen Fenpaed	2012 2010
Ipratropium bromide	Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml	Apo-Ipravent Ipratropium Steri-Neb Ipratropium Steri-Neb	2010
Iron polymaltose	Inj 50 mg per ml, 2 ml	Ferrum H	2011
Isotretinoin	Cap 10 mg & 20 mg	Oratane	2012
Itraconazole	Cap 100 mg	Sporanox	2010
Ketoconazole	Shampoo 2%	Sebizole	2011
Lactulose	Oral liq 10 g per 15 ml	Duphalac	2010
Latanoprost	Eye drops 50 µg per ml	Hysite	2012
Levobunolol	Eye drops 0.25% & 0.5%	Betagan	2010
Lignocaine hydrochloride	Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml	Xylocaine Xylocaine Xylocaine	2010
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5%; 30 g OP Crn 2.5% with prilocaine 2.5%; 5 g	EMLA EMLA	2010
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2012
Loperamide hydrochloride	Tab 2 mg	Nodia	2010
Loratadine	Tab 10 mg Oral liq 1 mg per ml	Loraclear Hayfever Relief Lorapaed	2010
Malathion	Liq 0.5% Shampoo 1%	Derbac M A-Lices	2010 2011
Mask for Spacer Device	Device	Foremount Child's Silicone Mask	30/9/11
Mebendazole	Tab 100 mg	De-Worm	2011
Mebeverine hydrochloride	Tab 135 mg	Colofac	2011
Medroxyprogesterone acetate	Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg	Provera	2010
Mesalazine	Enema 1 g per 100 ml	Pentasa	2012
Metformin hydrochloride	Tab immediate-release 500 mg & 850 mg	Apotex	2012
Methadone hydrochloride	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg	Biodone Biodone Forte Biodone Extra Forte Methatabs	2012 2010
Methotrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml	Methoblastin Methotrexate Ebewe Methotrexate Ebewe	2012 2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Methyl dopa	Tab 125 mg, 250 mg & 500 mg	Prodopa	2011
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2012
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml	Depo-Medrol	2011
Methylprednisolone acetate with lignocaine	Inj 40 mg per ml with lignocaine 1 ml	Depo-Medrol with Lidocaine	2011
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g	Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol	2012
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml	Pfizer	2011
Miconazole nitrate	Crn 2%	Multichem	2011
Mometasone furoate	Crn 0.1% Oint 0.1%	m-Mometasone m-Mometasone	2012
Morphine hydrochloride	Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	RA-Morph RA-Morph RA-Morph RA-Morph	2012
Morphine sulphate	Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml	Sevredol Mayne Mayne	2012 2011
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2010
Naltrexone hydrochloride	Tab 50 mg	ReVia	2010
Naproxen	Tab 250 mg Tab 500 mg	Noflam 250 Noflam 500	2012
Naproxen sodium	Tab 275 mg	Sonaflam	2010
Neostigmine	Inj 2.5 mg per ml, 1 ml	AstraZeneca	2010
Nevirapine	Oral suspension 10 mg per ml Tab 200 mg	Viramune Suspension Viramune	2012
Nicotine	Patch 7 mg, 14 mg & 21 mg Lozenge 1 mg & 2 mg Gum 2 mg & 4 mg (Fruit) Gum 2 mg & 4 mg (Mint)	Habitrol Habitrol Habitrol Habitrol	2010
Norethisterone	Tab 350 µg Tab 5 mg	Noriday 28 Primolut N	2012 2011
Nortriptyline hydrochloride	Tab 10 mg & 25 mg	Norpress	2011
Nystatin	Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u	Nilstat Nilstat Nilstat	2011 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Omeprazole	Cap 10 mg, 20 mg & 40 mg Inj 40 mg	Dr Reddy's Omeprazole Dr Reddy's Omeprazole	2011
Ondansetron	Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg	Zofran Zofran Zydis	2010
Oxybutynin	Tab 5 mg Oral liq 5 mg per 5 ml	Apo-Oxybutynin Apo-Oxybutynin	2010
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml & 2 ml Oral liq 5 mg per 5 ml	OxyNorm OxyNorm	2010
Oxytocin	Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml	Syntocinon Syntocinon Syntometrine	2012
Pamidronate disodium	Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml	Pamisol Pamisol Pamisol	2011
Pantoprazole	Inj 40 mg Tab 20 mg & 40 mg	Pantocid IV Dr Reddy's Pantoprazole	2010
Paracetamol	Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Pharmacare Paracare Junior Paracare Double Strength	2011
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin	Lacri-Lube	2010
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2010
Peak Flow Meter	Low range and Normal range	Breath-Alert	30/9/11
Pegylated interferon alpha-2A	Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168	Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack	31/12/12
Pergolide	Tab 0.25 mg & 1 mg	Permax	2011
Permethrin	Lotn 5%	A-Scabies	2011
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg & 500 mg	AFT AFT Cilicaine VK	2010
Phenylephrine hydrochloride	Eye drops 0.12%	Prefrin	2010
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Pizaccord	2012

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Pizotifen	Tab 500 µg	Sandomigran	2012
Poloxamer	Oral drops 10%	Coloxyl	2011
Polyvinyl alcohol	Eye drops 1.4% Eye drops 3%	Vistil Vistil Forte	2011
Potassium chloride	Tab long-acting 600 mg	Span-K	2012
Prazosin hydrochloride	Tab 1 mg, 2 mg & 5 mg	Apo-Prazo	2010
Prednisone	Tab 1 mg, 2.5 mg, 5 mg & 20 mg	Apo-Prednisone	2011
Prednisone sodium phosphate	Oral liq 5 mg per ml	Redipred	2012
Procaine penicillin	Inj 1.5 mega u	Cilicaine	2011
Promethazine	Tab 10 mg & 25 mg	Allersoothe	2011
Quinapril	Tab 5 mg, 10 mg & 20 mg	Accupril	2011
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg	Accuretic 10	2011
	Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 20	
Quinine sulphate	Tab 300 mg	Q 300	2012
Ranitidine hydrochloride	Oral liq 150 mg per 10 ml	Peptisoothe	2010
Rifabutin	Cap 150 mg	Mycobutin	2010
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg and 5 mg	Ropin	2010
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2012
Salbutamol	Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml	Asthalin	2012
		Asthalin	
		Salapin	
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	Duolin	2012
Selegiline hydrochloride	Tab 5 mg	Apo-Selegiline	2012
Simvastatin	Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg	Arrow-Simva 10 mg	2011
		Arrow-Simva 20 mg	
		Arrow-Simva 40 mg	
		Arrow-Simva 80 mg	
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2010
Sodium cromoglycate	Nasal spray, 4%	Rex	2012
Sotalol	Tab 80 mg & 160 mg	Mylan	2012
Spacer Device	230 ml	Space Chamber	30/9/11
Sumatriptan	Tab 50 mg & 100 mg	Arrow-Sumatriptan	2013
Syrup (pharmaceutical grade)	Liq	Midwest	2010
Tar with triethanolamine lauryl sulphate and fluorescein	Soln 2.3%	Pinetarsol	2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2010

Generic Name	Presentation	Brand Name	Expiry Date*
Temazepam	Tab 10 mg	Normison	2011
Terazosin hydrochloride	Tab 2 mg & 5 mg	Apo-Terazosin	2010
Terbinafine	Tab 250 mg	Apo-Terbinafine	2011
Testosterone cypionate	Inj long-acting 100 mg per ml, 10 ml	Depo-Testosterone	2011
Tetracosactrin	Inj 250 µg Inj 1 mg per ml, 1 ml	Synacthen Synacthen Depot	2011
Timolol maleate	Tab 10 mg Eye drops 0.25% & 0.5%	Apo-Timol Apo-Timop	2012 2011
Triamcinolone acetonide	Crn 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP	Aristocort Aristocort Kenacort-A40 Oracort	2011
Trimethoprim	Tab 300 mg	TMP	2011
Tropisetron	Cap 5 mg	Navoban	2012
Ursodeoxycholic acid	Cap 300 mg	Actigall	2011
Vancomycin hydrochloride	Inj 50 mg per ml, 10 ml	Pacific	2011
Zinc and castor oil	Oint BP	PSM	2011
Zinc sulphate	Cap 220 mg	Zincaps	2011
Zopiclone	Tab 7.5 mg	Apo-Zopiclone	2011

May changes in bold

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 May 2010

55	BENDROFLUAZIDE * Tab 2.5 mg – Up to 150 tab available on a PSO 7.58	500	✓ Arrow- Bendrofluazide
	May be supplied on a PSO for reasons other than emergency. * Tab 5 mg 11.75	500	✓ Arrow- Bendrofluazide
77	TESTOSTERONE UNDECANOATE – Retail pharmacy–Specialist Cap 40 mg 79.92	100	✓ Arrow-Testosterone
109	LIGNOCAINE Gel 2%, 10 ml urethral syringe 43.26	10	✓ Pfizer
138	FLUOROURACIL SODIUM Inj 50 mg per ml, 10 ml – PCT only – Specialist 24.75	5	✓ Fluorouracil Ebewe

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions

Effective 1 May 2010

34	DOCUSATE SODIUM – Only on a prescription * Tab Cap 50 mg 3.95 * Tab Cap 120 mg 5.49	100 100	✓ Laxofast 50 ✓ Laxofast 120
38	CALCIUM CARBONATE * Tab eff 1.75 g (1 g elemental) 6.54	30	✓ Calsource
38	CALCIUM CARBONATE * Tab 1.25 g (500 mg elemental) 9.18 * Tab 1.5 g (600 mg elemental) 10.33	250 250	✓ Calci-Tab 500 ✓ Calci-Tab 600
38	SODIUM FLUORIDE Tab 1.1 mg (0.5 mg elemental) 4.00	100	✓ PSM
38	FERROUS FUMARATE Tab 200 mg (65 mg elemental) 4.35	100	✓ Ferro-tab
38	FERROUS FUMARATE WITH FOLIC ACID Tab 310 mg (100 mg elemental) with folic acid 350 µg 4.75	60	✓ Ferro-F-Tabs
38	FERROUS GLUCONATE WITH ASCORBIC ACID * Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg 12.04	500	✓ Healtheries Iron with Vitamin C
39	FERROUS SULPHATE * Tab long-acting 325 mg (105 mg elemental) 5.06 (15.58) * ‡ Oral liq 150 mg per 5 ml (30 mg elemental per 1 ml) 10.30	150 500 ml	Ferro-Gradumet ✓ Ferodan
39	FERROUS SULPHATE WITH FOLIC ACID * Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg 1.80 (3.73)	30	Ferrograd-Folic
39	MAGNESIUM SULPHATE Inj 49.3%, 5 ml 26.60	10	✓ Mayne
39	ZINC SULPHATE * Cap 220 137.4 mg (50 mg elemental) 10.00	100	✓ Zincaps
138	GEMCITABINE HYDROCHLORIDE – PCT only – Specialist – Special Authority see SA1012 0877 Inj 1 g 245.00 349.20 Inj 200 mg 49.00 78.00 Inj 1 mg for ECP 0.26	1 1 1 mg	✓ Gemcitabine Ebewe ✓ Gemzar ✓ Gemcitabine Ebewe ✓ Gemzar ✓ Baxter

▶ SA1012 0877 Special Authority for Subsidy

Initial application - (Hodgkin's disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions - effective 1 May 2010 (continued)

continued...

All of the following

- 1 The patient has Hodgkin's disease*; and
- 2 Either
 - 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant.
- 3 Gemcitabine to be given for a maximum of 6 treatment cycles.

Initial application - (T-cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following

- 1 The patient has T-cell lymphoma*; and
- 2 Gemcitabine to be given for a maximum of 6 treatment cycles.

Initial application - (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has non small cell lung carcinoma (stage IIIa, or above); or
- 2 The patient has advanced malignant mesothelioma*; or
- 3 The patient has advanced pancreatic carcinoma; or
- 4 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or
- 5 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic).

Renewal - (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

143	VINORELBINE – PCT only – Specialist – Special Authority see SA1013 090†		
	Inj 10 mg per ml, 1 ml	24.00	1 ✓ Navelbine
		42.00	✓ Vinorelbine Ebewe
	Inj 10 mg per ml, 5 ml	120.00	1 ✓ Navelbine
		210.00	✓ Vinorelbine Ebewe
	Inj 1 mg for ECP	2.71	1 mg ✓ Baxter

▶ SA1013 090† Special Authority for Subsidy

Initial application - (Hodgkin's disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following

- 1 The patient has Hodgkin's disease*; and
- 2 Either
 - 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant.
- 3 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application - (T-cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

continued...

Changes to Restrictions - effective 1 May 2010 (continued)

continued...

All of the following

- 1 The patient has T-cell lymphoma*; and
- 2 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application – (**Other indications**) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has metastatic breast cancer; or
- 2 The patient has non-small cell lung cancer (stage IIIa, or above); or
- 3 All of the following:
 - 3.1 The patient has stage IB-IIIa non-small cell lung cancer; and
 - 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and
 - 3.3 The patient has good performance status (WHO/ECOG grade 0-1).

Renewal – (**Other Indications**) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 May 2010

61	CROTAMITON (↓ subsidy) a) Only on a prescription b) Not in combination Crm 10%	3.79 (4.45)	20 g OP		Eurax
63	CHLORHEXIDINE GLUCONATE – Subsidy by endorsement (↓ subsidy) a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. * Handrub 1% with ethanol 70%	4.60 (5.40)	500 ml		Orion
74	PREGNANCY TESTS - HCG URINE (↓ subsidy) a) Up to 200 test available on a PSO b) Only on a PSO Cassette	14.25 (19.00)	25 test OP		MDS Quick Card
95	LAMIVUDINE – Special Authority see SA0779 – Hospital pharmacy [HP1] (↓ subsidy) Tab 150 mg	153.60	60	✓3TC	
	Oral liq 10 mg per ml	50.00	240 ml OP	✓3TC	
136	CISPLATIN – PCT only – Specialist (↓ subsidy) Inj 1 mg per ml, 50 ml	15.00	1	✓Cisplatin Ebewe	
	Inj 1 mg per ml, 100 ml	21.00	1	✓Cisplatin Ebewe	
146	MEGESTROL ACETATE – Retail pharmacy-Specialist (↓ subsidy) Tab 160 mg	57.92 (74.25)	30		Megace

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✔ **fully subsidised**

Changes to Sole Subsidised Supply

Effective 1 May 2010

For the list of new Sole Subsidised Supply products effective 1 May 2010 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 9-17.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 May 2010

30	METFORMIN HYDROCHLORIDE				
	* Tab immediate-release 500 mg	8.09	500	✓ Arrow-Metformin	
	* Tab immediate-release 850 mg	6.67	250	✓ Arrow-Metformin	
37	CALCITRIOL				
	* Cap 0.25 µg	10.10	100	✓ Calcitriol-AFT	
	* Cap 0.5 µg	18.73	100	✓ Calcitriol-AFT	
65	PERMETHRIN				
	Crn 5%	3.65 (4.20)	30 g OP		Lyderm
65	WOOL FAT WITH MINERAL OIL – Only on a prescription				
	* Lotn hydrous 3% with mineral oil	1.12 (5.00)	200 ml OP		Alpha-Keri Lotion
		2.10 (9.38)	375 ml OP		Alpha-Keri Lotion
68	SUNSCREENS, PROPRIETARY – Subsidy by endorsement				
	Only if prescribed for a patient with severe photosensitivity secondary to a defined clinical condition and the prescription is endorsed accordingly.				
	Lotn	3.19 (8.82)	125 ml OP		Aquasun Sensitive SPF 30+
86	AMOXYCILLIN				
	Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO	1.27	100 ml	✓ Ranbaxy Amoxicillin	
117	LAMOTRIGINE				
	▲ Tab dispersible 200 mg	101.80	56	✓ Arrow-Lamotrigine	
119	SUMATRIPTAN				
	Tab 50 mg	1.55 (12.00) (22.00)	4		Sumagran Imigran
	Tab 100 mg	1.55 (12.00) (22.00)	2		Sumagran Imigran
143	TENIPOSIDE – PCT only – Specialist				
	Inj 10 mg per ml, 5 ml	845.11	10	✓ Vumon	
	Inj 50 mg for ECP	84.51	50 mg OP	✓ Baxter	
151	DEXTROCHLORPHENIRAMINE MALEATE				
	* Tab 2 mg	1.26 (5.60) 2.52 (9.99)	25 50		Polaramine Polaramine

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 August 2010

61	CROTAMITON a) Only on a prescription b) Not in combination Crm 10%	3.79 (4.45)	20 g OP		Eurax
63	CHLORHEXIDINE GLUCONATE – Subsidy by endorsement a) No more than 500 ml per month b) Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. * Handrub 1% with ethanol 70%	4.60 (5.40)	500 ml		Orion
74	PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette	14.25 (19.00)	25 test OP		MDS Quick Card
100	DICLOFENAC SODIUM * Tab long-acting 75 mg	3.10	30	✓	Diclax SR
	Note – Diclax SR tab long-acting 75 mg, 500 tab pack, remains listed.				
110	DEXTROPROPOXYPHENE WITH PARACETAMOL Tab napsylate 50 mg with paracetamol 325 mg	14.50 (22.50)	500		Paradex
	Cap hydrochloride 32.5 mg with paracetamol 325 mg	3.98 (4.90)	100		Capadex
		19.91 (33.14)	500		Capadex
146	MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg	57.92 (74.25)	30		Megace

Effective 1 November 2010

55	FUROSEMIDE * Tab 500 mg	12.00	100	✓	Diurin 500
62	HYDROCORTISONE * Crm 1% – Only on a prescription	2.44	100 g	✓	Lemnis Fatty Cream HC
72	ETHINYLLOESTRADIOL WITH LEVONORGESTREL * Tab ethinylloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinylloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinylloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab – Up to 84 tab available on a PSO.....	6.62	84	✓	Trifeme

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Items to be Delisted - effective 1 November 2010 (continued)

79	DYDROGESTERONE Tab 10 mg	27.50 (29.90)	50	Duphaston
	Note – Duphaston tab 10 mg, 28 tab pack remains listed.			
83	DANAZOL – Retail pharmacy-Specialist Cap 200 mg	29.35	30	✓ D-Zol
100	DICLOFENAC SODIUM * Tab long-acting 75 mg	22.78	500	✓ Apo-Diclo SR
	* Tab long-acting 100 mg	34.32	500	✓ Apo-Diclo SR
	Note – Diclax SR tab long-acting 75 mg, 500 tab pack, remains listed.			
112	CLOMIPRAMINE HYDROCHLORIDE Tab 25 mg	26.00	500	✓ Clopress
113	MOCLOBEMIDE Note: There is a significant cost differential between moclobemide and fluoxetine (moclobemide being about three times more expensive). For depressive syndromes it is therefore more cost-effective to start treatment with fluoxetine first before considering prescribing moclobemide.			
	Tab 150 mg	8.31	60	✓ GenRx Moclobemide
	Tab 300 mg	18.80	60	✓ GenRx Moclobemide
138	FLUOROURACIL SODIUM Inj 50 mg per ml, 10 ml – PCT only – Specialist.....	4.95	1	✓ Fluorouracil Ebewe
	Note – Fluorouracil Ebewe inj 50 mg per ml, 10 ml, 5 injection pack listed 1 May 2010.			

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II

Effective 1 May 2010

BENDROFLUAZIDE

Tab 2.5 mg.....	Arrow-Bendrofluzide	7.58	500	1%	Jul-10	Neo-Naclex
Tab 5 mg.....	Arrow-Bendrofluzide	11.75	500	1%	Jul-10	Neo-Naclex

CISPLATIN (↓ price and addition of HSS)

Inj 1 mg per ml, 50 ml.....	Cisplatin Ebewe	15.00	1	1%	Jul-10	DBL Cisplatin
Inj 1 mg per ml, 100 ml.....	Cisplatin Ebewe	21.00	1	1%	Jul-10	DBL Cisplatin

Note – Mayne cisplatin inj 1 mg per ml, 50 ml and 100 mg, to be delisted 1 July 2010.

CLINDAMYCIN (addition of HSS)

Inj phosphate 150 mg per ml, 4 ml.....	Dalacin C	16.00	1	1%	Jul-10	(B)
---	------------------	-------	---	----	--------	-----

CLOMIPRAMINE HYDROCHLORIDE

Tab 25 mg.....	Clopress	26.00	500			
----------------	----------	-------	-----	--	--	--

Note – Clopress tab 25 mg to be delisted 1 July 2010.

DANAZOL

Cap 200 mg.....	D-Zol	29.35	30			
-----------------	-------	-------	----	--	--	--

Note – D-Zol cap 200 mg to be delisted 1 November 2010.

DOCUSATE SODIUM (correction of presentation)

Cap tab 50 mg.....	Laxofast 50	3.95	100	1%	Jun-10	Coloxyl
Cap tab 120 mg.....	Laxofast 120	5.49	100	1%	Jun-10	Coloxyl

FLUOROURACIL SODIUM (addition of new pack size)

Inj 50 mg per ml, 10 ml.....	Fluorouracil Ebewe	24.75	5	1%	Oct-07	Mayne
------------------------------	---------------------------	-------	---	----	--------	-------

Note – Fluorouracil Ebewe inj 50 mg per ml, 10 ml, 1 injection pack, to be delisted 1 July 2010.

FUROSEMIDE

Tab 500 mg.....	Diurin 500	12.00	100			
-----------------	------------	-------	-----	--	--	--

Note – Diurin 500 tab 500 mg to be delisted 1 July 2010.

LIGNOCAINE

Gel 2%, 10 ml urethral syringe.....	Pfizer	43.26	10			
-------------------------------------	--------	-------	----	--	--	--

MEDROXYPROGESTERONE ACETATE (addition of HSS)

Inj 150 mg per ml, 1 ml, syringe.....	Depo-Provera	7.15	1	1%	Jul-10	(B)
---------------------------------------	---------------------	------	---	----	--------	-----

MEDROXYPROGESTERONE ACETATE (continuation of HSS)

Tab 2.5 mg.....	Provera	3.09	30	1%	Jul-10	Cytrin
Tab 5 mg.....	Provera	13.06	100	1%	Jul-10	Cytrin
Tab 10 mg.....	Provera	6.85	30	1%	Jul-10	Cytrin
Tab 100 mg.....	Provera	96.50	100	1%	Jul-10	(B)
Tab 200 mg.....	Provera	70.50	30	1%	Jul-10	(B)

Products with Hospital Supply Status (HSS) are in **bold**.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes Part II - effective 1 May 2010 (continued)

MOCLOBEMIDE (reinstatement of HSS)

Tab 150 mg.....	Apo-Moclobemide	69.23	500	1%	May-10	GenRx Moclobemide
Tab 300 mg.....	Apo-Moclobemide	31.33	100	1%	May-10	GenRx Moclobemide

Note – GenRx Moclobemide tab 150 mg and 300 mg to be delisted 1 May 2010.

TENOXICAM

Inj 20 mg.....	AFT	9.95	1	1%	Jul-10	(B)
----------------	------------	------	---	----	--------	-----

TESTOSTERONE UNDECANOATE

Cap 40 mg	Arrow-Testosterone	79.92	100	1%	Jul-10	Andriol Testocaps Panteston
-----------------	---------------------------	-------	-----	----	--------	--------------------------------

Effective 1 April 2010

AMBRISENTAN

Tab 5 mg.....	Volibris	4,585.00	30			
Tab 10 mg.....	Volibris	4,585.00	30			

BISACODYL

Suppos 5 mg.....	Dulcolax	3.00	6			
Suppos 10 mg.....	Dulcolax	3.00	6			

CHLORAMPHENICOL (↑ price)

Eye drops 0.5%	Chlorsig	2.40	10 ml			
----------------------	----------	------	-------	--	--	--

CIPROFLOXACIN (↓ price and addition of HSS)

Inj 2 mg per ml, 100 ml	Aspen Ciprofloxacin	41.00	10	1%	Jun-10	Ciproxin DBL DP-Cipro Topistin Ufexil
-------------------------------	----------------------------	-------	----	----	--------	---

DANAZOL

Cap 200 mg	Azol	97.83	100			
------------------	------	-------	-----	--	--	--

DIHYDROCODEINE TARTRATE

Tab long-acting 60 mg.....	DHC Continus	27.27	60	1%	Jun-10	(B)
----------------------------	---------------------	-------	----	----	--------	-----

DOCUSATE SODIUM

Tab 50 mg.....	Laxofast 50	3.95	100	1%	Jun-10	Coloxyl
Tab 120 mg.....	Laxofast 120	5.49	100	1%	Jun-10	Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES (↓ price and addition of HSS)

Tab 50 mg with total sennosides 8 mg	Laxsol	6.38	200	1%	Jun-10	Coloxyl with Senna
--	---------------	------	-----	----	--------	--------------------

HYDROCORTISONE

Crm 1%.....	Pharmacy Health	3.75	100 g			
-------------	-----------------	------	-------	--	--	--

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes Part II - effective 1 April 2010 (continued)

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN (Amended chemical name)

Crm 1% with natamycin 1% and neomycin sulphate 0.5%	Pimafucort	2.79	15 g			
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	Pimafucort	2.79	15 g			

OMEPRAZOLE

Cap 10 mg	Dr Reddy's Omeprazole	2.00	28	1%	May-09	Losec
Cap 20 mg	Dr Reddy's Omeprazole	2.85	28	1%	May-09	Losec
Cap 40 mg	Dr Reddy's Omeprazole	3.35	28	1%	May-09	Losec
						Omezol

Note – Dr Reddy's Omeprazole cap 10 mg, 20 mg and 40 mg, 28 cap packs, to be delisted 1 June 2010. Please note that the 30 capsule packs remain listed.

PIPERACILLIN SODIUM WITH TAZOBACTAM SODIUM

Inj 4 g with tazobactam sodium 500 mg	Tazocin EF	12.00	1	1%	Jun-10	DBL Zobacin
---	-------------------	-------	---	----	--------	----------------

TOPIRAMATE

Tab 25 mg	Arrow	11.07	60			
	-Topiramate					
Tab 50 mg	Arrow	18.81	60			
	-Topiramate					
Tab 100 mg	Arrow	31.99	60			
	-Topiramate					
Tab 200 mg	Arrow	55.19	60			
	-Topiramate					

TRANEXAMIC ACID (↓ price and addition of HSS)

Tab 500 mg	Cyclokapron	32.92	100	1%	Jun-10	(B)
------------------	--------------------	-------	-----	----	--------	-----

ZIDOVUDINE (AZT)

Cap 100 mg	Retrovir	145.00	100	1%	Jun-10	(B)
Oral liq 10 mg per ml	Retrovir	29.00	200 ml	1%	Jun-10	(B)

Section H changes to Part IV

Effective 1 April 2010

CLOPIDOGREL

Tab 75 mg	Plavix
-----------	---------------

Up to 4 weeks supply post stenting. Not to be funded for acute coronary syndrome or transient ischaemic attacks.

Index

Pharmaceuticals and brands

Symbols

3TC 22

A

Alpha-Keri Lotion 24

Ambrisentan 28

Amoxicillin 24

Apo-Diclo SR 26

Apo-Moclobemide 28

Aquasun Sensitive SPF 30+ 24

Arrow-Bendrofluazide 18, 27

Arrow-Lamotrigine 24

Arrow-Metformin 24

Arrow-Testosterone 18, 28

Arrow-Topiramate 29

Aspen Ciprofloxacin 28

Azol 28

B

Bendrofluazide 18, 27

Bisacodyl 28

C

Calcitriol 24

Calcitriol-AFT 24

Calci-Tab 500 19

Calci-Tab 600 19

Calcium carbonate 19

Calsource 19

Capadex 25

Chloramphenicol 28

Chlorhexidine gluconate 22, 25

Chlorsig 28

Ciprofloxacin 28

Cisplatin 22, 27

Cisplatin Ebewe 22, 27

Ciindamycin 27

Clomipramine hydrochloride 26, 27

Clopidogrel 29

Clopress 26, 27

Crotamiton 22, 25

Cyclokapron 29

D

D-Zol 26, 27

Dalacin C 27

Danazol 26, 27, 28

Depo-Provera 27

Dextrochlorpheniramine maleate 24

Dextropropoxyphene with paracetamol 25

DHC Continus 28

Diclax SR 25

Diclofenac sodium 25, 26

Dihydrocodeine tartrate 28

Diurin 500 25, 27

Docusate sodium 19, 27, 28

Docusate sodium with sennosides 28

Dr Reddy's Omeprazole 29

Dulcolax 28

Duphaston 26

Dydrogesterone 26

E

Ethinylloestradiol with levonorgestrel 25

Eurax 22, 25

F

Ferodan 19

Ferro-F-Tabs 19

Ferro-Gradumet 19

Ferro-tab 19

Ferrograd-Folic 19

Ferrous fumarate 19

Ferrous fumarate with folic acid 19

Ferrous gluconate with ascorbic acid 19

Ferrous sulphate 19

Ferrous sulphate with folic acid 19

Fluorouracil Ebewe 18, 26, 27

Fluorouracil sodium 18, 26, 27

Furosemide 25, 27

G

Gemcitabine Ebewe 19

Gemcitabine hydrochloride 19

Gemzar 19

GenRx Moclobemide 26

H

Healtheries Iron with Vitamin C 19

Hydrocortisone 25, 28

Hydrocortisone with natamycin and neomycin 29

I

Imigran 24

L

Lamivudine 22

Lamotrigine 24

Laxofast 50 19, 27, 28

Laxofast 120 19, 27, 28

Laxsol 28

Lemnis Fatty Cream HC 25

Lignocaine 18, 27

Lyderm 24

M

Magnesium sulphate 19

MDS Quick Card 22, 25

Medroxyprogesterone acetate 27, 28

Megace 22, 25

Megestrol acetate 22, 25

Metformin hydrochloride 24

Moclobemide 26, 28

N

Navelbine 20

Index

Pharmaceuticals and brands

O

Omeprazole..... 29

P

Paradox 25

Permethrin 24

Pharmacy Health 28

Pimafucort 29

Piperacillin sodium with tazobactam sodium..... 29

Plavix..... 29

Polaramine..... 24

Pregnancy tests - hCG urine 22, 25

Provera 27

R

Ranbaxy Amoxicillin 24

Retrovir 29

S

Sodium fluoride..... 19

Sumagran 24

Sumatriptan 24

Sunscreens, proprietary 24

T

Tazocin EF 29

Teniposide 24

Tenoxicam 28

Testosterone undecanoate..... 18, 28

Topiramate..... 29

Tranexamic acid..... 29

Trifeme 25

V

Vinorelbine..... 20

Vinorelbine Ebewe..... 20

Volibris 28

Vumon..... 24

W

Wool fat with mineral oil 24

Z

Zidovudine (AZT)..... 29

Zincaps 19

Zinc sulphate..... 19

Index

Pharmaceuticals and brands

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Freephone Information line (9am-5pm weekdays) 0800 66 00 50

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)



While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.